This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, H. C.
Right arrow Articles by Stark, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, H. C.
Right arrow Articles by Stark, A. R.
PEDIATRICS Vol. 110 No. 1 July 2002, pp. 200-201

Premature Conclusions on Postnatal Steroid Effects

Harris C. Jacobs, MD
Rachel L. Chapman, MD
Ian Gross, MD
Division of Neonatology
Bridgeport Hospital
Department of Pediatrics
Bridgeport, CT 06610
Division of Neonatology
Yale University
Department of Pediatrics
New Haven, CT

The first 20% of the full text of this article appears below.

To the Editor.—

We read with interest the recent joint statement of the AAP, Committee on the Fetus and Newborn and the Canadian Paediatric Society, Fetus and Newborn Committee,1 the recent letter to the editor by Taylor et al,2 and the response by Dr Barrington3 on the topic of postnatal glucocorticoids for chronic lung disease in the neonate. The use of steroids, dexamethasone in particular, to treat or prevent chronic lung disease (CLD) is controversial. Although we applaud the efforts of the Academy to bring some sense to this quagmire, we have serious reservations about some of the conclusions and recommendations.

Our major concern is that conclusions in the AAP report relating to neurodevelopmental outcome after glucocorticoid treatment were based largely on 2 published meta-analyses performed on 54 and 8 studies5 that appear to be seriously flawed. In a comment on the latter paper, Taylor et al2 discussed the impropriety of combining 8 heterogeneous studies that differed in age at initiation of glucocorticoid therapy, dose and duration of therapy, and tests (and timing of these tests) used to determine neurodevelopmental outcome. Their succinct and valid arguments apply equally well to the meta-analysis of 5 studies,4 and need not be repeated. It was disappointing to note that the AAP report accepted the findings of these 2 analyses without any stated reservations and then went on to recommend restrictive conditions for using postnatal glucocorticoids.

Review of the 11 studies listed in the AAP report reveals that in 5, glucocorticoid therapy was initiated in the first 4 days after birth and in the remaining 6, therapy was begun . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. B. Clerch, A. S. Baras, G. D. Massaro, E. P. Hoffman, and D. Massaro
DNA microarray analysis of neonatal mouse lung connects regulation of KDR with dexamethasone-induced inhibition of alveolar formation
Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L411 - L419.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Perlman
Concern About Fetus and Newborn Committee Statement on Corticosteroid Use
Pediatrics, November 1, 2002; 110(5): 1034 - 1034.
[Full Text] [PDF]